For: | Xue Y, Zhang LX, Wang L, Li T, Qu YD, Liu F. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. World J Gastroenterol 2017; 23(32): 5969-5976 [PMID: 28932089 DOI: 10.3748/wjg.v23.i32.5969] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v23/i32/5969.htm |
Number | Citing Articles |
1 |
Yuvaram N. V. Reddy, David Nunes, Vipul Chitalia, Craig E. Gordon, Jean M. Francis. Hepatitis C virus infection in kidney transplantation‐changing paradigms with novel agents. Hemodialysis International 2018; 22(S1) doi: 10.1111/hdi.12659
|
2 |
Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir. Canadian Journal of Gastroenterology and Hepatology 2020; 2020: 1 doi: 10.1155/2020/1632959
|
3 |
Hossam Gewaid, Ahmed A. Mesalam, Ahmed A. Ibrahim, Dina N. Abdel Shafy, Rola N. Abdel Shafy, Nahed Emara, Soha M. Hamdy, Mohy Gewaid, Mahmoud M. Bahgat. Establishment of a platform for molecular and immunological characterization of the RNA‐dependent‐RNA‐polymerase NS5B of an Egyptian HCV isolate. Journal of Medical Virology 2018; 90(3): 545 doi: 10.1002/jmv.24977
|
4 |
Radwa Samir Hagag, Morkoss Medhat Fakhry, Ossama Ashraf Ahmed, Shaimaa Abdalaleem Abdalgeleel, Mahasen Aly Radwan, Gina Gamal Naguib. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. The Egyptian Journal of Internal Medicine 2022; 34(1) doi: 10.1186/s43162-022-00126-8
|
5 |
Cahyani Gita Ambarsari, Eka Laksmi Hidayati, Irsan Hasan, Angela Grace, Hanifah Oswari. <p>Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series</p>. International Journal of Nephrology and Renovascular Disease 2020; : 139 doi: 10.2147/IJNRD.S248632
|
6 |
Hany Mohammed Ibrahim, Faten Roshdy Abdel-Ghaffar, Ahmed Bahgat Zied, Sameha Husni El-Ghareeb. Assessment of the Sofosbuvir + Daclatasvir (±) Ribavirin Treatment and the Prognostic Efficacy of Interferon-gamma Induced Protein 10, Macrophage Inflammatory-1-Beta, and C-reactive Protein in Hepatitis C Egyptian Patients' Therapy Outcome. Biomedical and Biotechnology Research Journal (BBRJ) 2022; 6(1): 109 doi: 10.4103/bbrj.bbrj_209_21
|
7 |
Matthew Kadatz, Scott Klarenbach, Jagbir Gill, John S. Gill. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test–positive donors for transplantation in hepatitis C–negative recipients. American Journal of Transplantation 2018; 18(10): 2457 doi: 10.1111/ajt.14929
|
8 |
Sreekumar Othumpangat, John D. Noti. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2018; 40: 345 doi: 10.1016/bs.seda.2018.08.005
|
9 |
Aamir Bashir, Ashish Verma, Ajay Duseja, Arka De, Pramil Tiwari. Adjuvant Use of Ribavirin With Treatment of Hepatitis C Virus in Kidney Transplant Recipients. Indian Journal of Transplantation 2022; 16(3): 243 doi: 10.4103/ijot.ijot_10_22
|
10 |
Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar AC, Sanjay Hadigal. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World Journal of Gastroenterology 2019; 25(29): 3897-3919 doi: 10.3748/wjg.v25.i29.3897
|